US biobanker retreats from Europe
This article was originally published in Scrip
Executive Summary
Europe's life sciences industry is losing one of its most influential supporters when it comes to raising new capital. US investment bank Piper Jaffray has announced plans to restructure its European operations by focusing resources on what it believes to be its two areas of strength -- the distribution of US and Asian securities to Europe's institutional investors, as well as merger-and-acquisition advisory services to European clients. The firm will no longer be involved in selling European-listed biotech stocks.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.